Race-ethnic disparities in birth outcomes are well established, and new research suggests that there may also be important sexual identity disparities in birth weight and preterm birth. This study uses the National Longitudinal Study of Adolescent to Adult Health and is the first to examine disparities in birth outcomes at the intersection of race-ethnicity and sexual identity. We use ordinary least sqaures and logistic regression models with live births (n = 10,318) as the unit of analysis clustered on mother ID (n = 5,105), allowing us to adjust for preconception and pregnancy-specific perinatal risk factors as well as neighborhood characteristics. Results show a striking reversal in the effect of lesbian or bisexual identity on birth outcomes across race-ethnicities For white women, a bisexual or lesbian identity is associated with better birth outcomes than their white heterosexual counterparts, but for Black and Latina women, it is associated with worse birth outcomes than their heterosexual peers.Background In the last two decades the world has experienced many outbreaks of infectious diseases including the coronavirus disease 2019 (COVID-19) pandemic. COVID-19 was first reported in China and spread to more than 200 countries and territories. At present, there are no available treatment and vaccines for COVID-19. This study aimed to evaluate the global research trends in COVID-19 vaccine.Methods On January 12, 2020, a comprehensive search of documents on COVID-19 was conducted in the Web of Science Core Collection database. HistCiteTM and VOSviewer softwares are used for citations and visualization mapping.Results A total of 916 documents authored by 4,392 authors and published in 376 journals were included in the final analysis. Majority of the retrieved documents consisted of articles (n = 372, 40.6%). The most prolific authors were Dhama K (n = 10, 1.1%) and Hotez PJ (n = 10, 1.1%). The most active institution was the University of Oxford (n = 24, 2.6%). The leading journal in COVID-19 vaccine was Human Vaccine & Immunotherapeutics (n = 43, 4.7%). The most frequently used keywords were COVID (n = 597, 65.2%), and vaccine (n = 521, 56.9%). Furthermore, visualization mapping shows that COVID-19 was the most co-occurrence author keyword. The United States of America (USA) was the most productive country, 352 (38.4%).Conclusions This is the first bibliometric study that provides detailed information about published literature on the COVID-19 vaccine. Majority of the publications were published in developed countries. The findings may useful for researchers and policymakers.This study investigated the relationship between front foot contact (FFC) ground reaction forces (GRF) during the delivery stride, lower-limb strength, eccentric dexterity and power, and ball release speed (BRS) among pace bowlers. Thirteen high-level male pace bowlers performed double and single leg drop landings; isometric mid-thigh pull; countermovement jump; and pace bowling (two-over bowling spell measuring BRS and FFC GRF). The relationship between assessed variables and BRS was determined via frequentist and Bayesian multiple linear regression. The model including peak braking force was the most probable given the data (Bayes Factor=1.713) but provided only weak evidence in comparison to the null model. The results of frequentist and Bayesian modelling were comparable with peak braking force explaining 23.3% of the variance in BRS (F(1, 11)=4.64, P=0.054). Results indicate pace bowlers with greater peak braking GRF during FFC generally elicit higher BRS. However, the weak relationship between peak braking force and BRS, and the lack of a linear relationship between BRS and other variables, highlights the complexities and inter-individual variability inherent to pace bowling at a high-level. A more individual-focused analysis revealed varied strategies within pace bowlers to deliver the outcome (e.g., BRS) and should be considered in future study designs. The antimicrobial peptide hCAP18/LL-37 is detected in desquamated epithelial cells of human whole saliva, but the functional importance of this pool of hCAP18/LL-37 is not understood. Here, we assess the impact of homogenates of desquamated oral epithelial cells and exogenous, synthetic LL-37 on two oral bacteria and . Desquamated epithelial cells of unstimulated whole saliva were isolated and cellular and extracellular levels of hCAP18/LL-37 analyzed by ELISA. Bacterial viability was determined by BacLight Live/Dead staining and confocal laser scanning microscopy. Desquamated oral epithelial cells harboured hCAP18/LL-37, and they spontaneously released/leaked the peptide to their medium. Exogenous, synthetic LL-37 showed cytotoxic activity against but not , suggesting that LL-37 acts differentially on these two types of oral bacteria. Homogenates of desquamated oral epithelial cells had no effect on viability. Treatment with exogenous, synthetic LL-37 (8 and 10 μM) reduced viability, whereas lower concentrations (0.1 and 1 µM) of the peptide lacked effect. Desquamated oral epithelial cells contain hCAP18/LL-37, but their cellular levels of hCAP18/LL-37 are too low to affect viability, whereas exogenous, synthetic LL-37 has a strong effect on these bacteria.Desquamated oral epithelial cells contain hCAP18/LL-37, but their cellular levels of hCAP18/LL-37 are too low to affect S. check details mutans viability, whereas exogenous, synthetic LL-37 has a strong effect on these bacteria. Several novel beta-lactams (BLs) and/or beta lactams/beta-lactamase inhibitors (BL/BLIs) have been recently developed for the management of multidrug-resistant bacterial infections. Data concerning dose optimization in critically ill patients with altered renal function are scanty. This article provides a critical reappraisal of pharmacokinetic and clinical issues emerged with novel BLs and/or BL/BLIs in renal critically ill patients. Clinical and pharmacokinetic studies published in English until December 2020 were searched on the PubMed-MEDLINE database. Several issues emerged with the use of novel BLs and/or BL/BLIs in critically ill renal patients. Suboptimal clinical response rate with ceftazidime-avibactam and ceftolozane-tazobactam was reported in phase II-III trials in patients with moderate kidney injury; data on patients undergoing renal replacement therapy are limited to some case reports; dose adjustment in augmented renal clearance is provided only for cefiderocol. Implementation of altered dosing strategies (prolonged infusion and/or higher dosage) coupled with adaptive real-time therapeutic drug monitoring could represent the most effective approach in warranting optimal pharmacokinetic/pharmacodynamic targets with novel BLs and/or BL/BLIs in challenging scenarios, thus minimizing the risk of clinical failure and/or of resistance selection.